keyword
MENU ▼
Read by QxMD icon Read
search

febrile neutropenia in cancer

keyword
https://www.readbyqxmd.com/read/29330005/a-phase-i-study-of-irinotecan-capecitabine-xeloda-and-oxaliplatin-in-patients-with-advanced-colorectal-cancer
#1
Jean Maroun, Horia Marginean, Derek Jonker, Christine Cripps, Rakesh Goel, Timothy Asmis, Rachel Goodwin, Gabriela Chiritescu
BACKGROUND: The objective of the present phase I study was to define the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of irinotecan, capecitabine, and oxaliplatin given in combination (IXO regimen) to patients with previously untreated, unresectable advanced or metastatic colorectal cancer (CRC). PATIENTS AND METHODS: Patients received oxaliplatin followed by irinotecan as intravenous infusions on day 1, with oral capecitabine taken twice daily (BID) on days 2 to 15 of a 3-week cycle...
December 15, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29318740/risk-of-febrile-neutropenia-and-early-treatment-cessation-in-men-receiving-standard-and-dose-reduced-3-weekly-docetaxel-for-metastatic-castration-resistant-prostate-cancer
#2
Anis A Hamid, Kaspar Willson, Andrew D Vincent, Babak Tamjid, Margaret Lee, Alice Bergin, Chun Gan, Ainsley Campbell, Josephine Stewart, Carmel Pezaro, Ben Tran, Andrew J Weickhardt
BACKGROUND: Docetaxel is an effective therapy for metastatic castration-resistant prostate cancer (mCRPC); however, many patients experience febrile neutropenia (FN) and cease treatment early due to toxicity. It is not known whether lower dose (LD) q3-weekly docetaxel impacts toxicity or efficacy. METHODS: Multicenter retrospective study included 166 patients with mCRPC who received q3-weekly docetaxel between 2010 and 2015. Demographic, disease, chemotherapy (standard dose, SD>60 mg/m2 vs LD≤60 mg/m2 ) and toxicity data were collected...
January 10, 2018: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29317553/safety-profile-of-biosimilar-filgrastim-zarzio-zarxio-a-combined-analysis-of-phase-iii-studies
#3
Nadia Harbeck, Pere Gascón, Andriy Krendyukov, Nadja Hoebel, Sreekanth Gattu, Kimberly Blackwell
BACKGROUND: Evaluation of adverse events (AEs) in pivotal registration trials and ongoing postmarketing surveillance is important for all biologics, including biosimilars. A combined analysis of two pivotal registration studies was performed to strengthen evidence on safety for biosimilar filgrastim EP2006 in patients with breast cancer receiving myelosuppressive chemotherapy, a sensitive clinical setting to confirm biosimilarity of filgrastim. MATERIALS AND METHODS: Data were combined from two phase III studies of biosimilar filgrastim EP2006...
January 9, 2018: Oncologist
https://www.readbyqxmd.com/read/29316288/carboplatin-plus-pemetrexed-for-the-elderly-incurable-chemo-naive-nonsquamous-non-small-cell-lung-cancer-meta-analysis
#4
Masaru Ito, Nobuyuki Horita, Akimichi Nagashima, Takeshi Kaneko
AIM: In some developed countries, a proportion of nonsquamous non-small cell lung cancer (NSq NSCLC) patients are aged over 70 years when they are diagnosed. However, evidence of lung cancer chemotherapy usually comes from randomized controlled trials that only recruit younger patients with good performance status. In daily practice, less-toxic carboplatin + pemetrexed regimen is often used for elderly patients, although this regimen is not sufficiently supported by rigid evidence for elderly cases...
January 8, 2018: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29290024/a-multi-institution-phase-ii-study-of-docetaxel-and-s-1-in-combination-with-trastuzumab-for-her2-positive-advanced-gastric-cancer-dash-study
#5
Shunsuke Kagawa, Atsushi Muraoka, Takeshi Kambara, Hiroshi Nakayama, Ryosuke Hamano, Norimitsu Tanaka, Kazuhiro Noma, Kohji Tanakaya, Hiroyuki Kishimoto, Kunitoshi Shigeyasu, Shinji Kuroda, Satoru Kikuchi, Kazuya Kuwada, Masahiko Nishizaki, Yasuhiro Shirakawa, Toshiyoshi Fujiwara
BACKGROUND: Trastuzumab when combined with fluoropyrimidine and cisplatin was proven to improve survival in patients with human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC) in the ToGA study. The safety and efficacy of trastuzumab in combination with docetaxel and S-1 have not yet been evaluated. METHODS: This study was a multicenter, phase II study. Patients with chemotherapy-naïve HER2-positive advanced or metastatic GC were eligible...
December 30, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29288764/brief-report-tivantinib-in-combination-with-erlotinib-versus-erlotinib-alone-for-egfr-mutant-nsclc-an-exploratory-analysis-of-the-phase-3-marquee-study
#6
Giorgio V Scagliotti, Dale Shuster, Sergey Orlov, Joachim von Pawel, Frances A Shepherd, Jeffrey S Ross, Qiang Wang, Brian Schwartz, Wallace Akerley
INTRODUCTION: This exploratory subgroup analysis of the MARQUEE study evaluated the efficacy and safety of erlotinib plus tivantinib in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). METHODS: Patients with advanced, non-squamous, EGFR and mesenchymal-epithelial transition (MET) inhibitor-naive NSCLC, previously treated with 1 to 2 lines of systemic therapy, were randomized to oral erlotinib (150 mg once daily) plus tivantinib (360 mg twice daily) or to erlotinib plus placebo...
December 27, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29286572/predicting-bacterial-infections-among-pediatric-cancer-patients-with-febrile-neutropenia-external-validation-of-the-picnicc-model
#7
Rohit P Ojha, Peter H Asdahl, Ewout W Steyerberg, Henrik Schroeder
INTRODUCTION: The Predicting Infectious Complications in Neutropenic Children and Young People with Cancer (PICNICC) model was recently developed for antibiotic stewardship among pediatric cancer patients, but limited information is available about its clinical usefulness. We aimed to assess the performance of the PICNICC model for predicting microbiologically documented bacterial infections among pediatric cancer patients with febrile neutropenia. MATERIALS AND METHODS: We used data for febrile neutropenia episodes at a pediatric cancer center in Aarhus, Denmark between 2000 and 2016...
December 29, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29285832/nimotuzumab-combined-with-concurrent-chemoradiotherapy-in-japanese-patients-with-esophageal-cancer-a-phase-i-study
#8
Ken Kato, Takashi Ura, Wasaburo Koizumi, Satoru Iwasa, Chikatoshi Katada, Mizutomo Azuma, Satoshi Ishikura, Yoshinori Nakao, Hiroshi Onuma, Kei Muro
Nimotuzumab is a humanized anti-epidermal growth factor receptor IgG1 monoclonal antibody. This phase I study assessed the tolerability, safety, efficacy, and PK of nimotuzumab in combination with chemoradiotherapy in Japanese patients with esophageal cancer. Patients with stage II, III, and IV esophageal cancer were enrolled. Patients were planned to receive nimotuzumab (level 1: 200 mg/week for 25 weeks; or level 2: 400 mg/week in the chemoradiation period, 400 mg biweekly in an additional chemotherapy period [8 weeks after the chemoradiation period] and a maintenance therapy period [after chemotherapy to 25 weeks]) combined with cisplatin (75 mg/m2 on day 1) and fluorouracil (1000 mg/m2 on days 1 to 4) in the chemoradiation and additional chemotherapy periods...
December 29, 2017: Cancer Science
https://www.readbyqxmd.com/read/29282494/incidence-of-neutropenia-and-use-of-granulocyte-colony-stimulating-factors-in-multiple-myeloma-is-current-clinical-practice-adequate
#9
REVIEW
Xavier Leleu, Francesca Gay, Anne Flament, Kim Allcott, Michel Delforge
Although immunomodulatory drugs, alkylating agents, corticosteroids, protease inhibitors, and therapeutic monoclonal antibodies improve multiple myeloma outcomes, treatment burden is still an issue. Neutropenia is a known complication of cytotoxic cancer therapy and is often associated with infections; it is an important consideration in myeloma given the fact that patients often have a weakened immune system. The risk of febrile neutropenia increases with severe and persisting neutropenia. Recombinant granulocyte colony-stimulating factors (G-CSFs) are commonly used to reduce the incidence, duration, and severity of febrile neutropenia...
December 27, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/29281873/safety-results-and-analysis-of-eribulin-efficacy-according-to-previous-microtubules-inhibitors-sensitivity-in-the-french-prospective-expanded-access-program-for-heavily-pre-treated-metastatic-breast-cancer
#10
Renaud Sabatier, Véronique Diéras, Xavier Pivot, Etienne Brain, Henri Roché, Jean-Marc Extra, Audrey Monneur, Magali Provansal, Carole Tarpin, François Bertucci, Patrice Viens, Christophe Zemmour, Anthony Gonçalves
Purpose: Eribulin is approved for advanced breast cancers refractory to anthracyclines and taxanes. Efficacy according to sensitivity to previous therapies has been poorly explored. Materials and Methods: Safety data were collected prospectively and we retrospectively collected efficacy data from the five French centres that participated in the Eribulin E7389-G000-398 expanded access program. Our main objectives were exploration of safety and analysis of eribulin efficacy (progression-free survival [PFS] and overall survival [OS]) according to sensitivity to the last microtubule-inhibiting agent administered...
December 28, 2017: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/29261479/managing-patients-with-oncologic-complications-in-the-emergency-department
#11
David Wacker, Michael T McCurdy
As the prevalence of cancer continues to increase in the general population and improvements in cancer treatment prolong survival, the incidence of patients presenting to the emergency department with oncologic complications will, similarly, continue to rise. This issue reviews 3 of the more common presentations of oncology patients to the emergency department: metastatic spinal cord compression, tumor lysis syndrome, and febrile neutropenia. Signs and symptoms of these conditions can be varied and nonspecific, and may be related to the malignancy itself or to an adverse effect of the cancer treatment...
January 2018: Emergency Medicine Practice
https://www.readbyqxmd.com/read/29243107/impact-of-geriatric-assessment-for-the-therapeutic-decision-making-of-breast-cancer-results-of-a-french-survey-afsos-and-sofog-collaborative-work
#12
Claire Falandry, Ivan Krakowski, Hervé Curé, Elisabeth Carola, Pierre Soubeyran, Olivier Guérin, Hélène Gaudin, Gilles Freyer
BACKGROUND: Cancer management in the elderly is often considered as suboptimal, highly variable, and rarely evidence-based. Data are needed to understand decision-making processes in this population. MATERIALS AND METHODS: A survey was performed in France to describe decision-making in gynaecologic patients over 70. It followed a three-step method: (1) 101 representative physicians questioned about treatment decision criteria; (2) simplified individual data were collected; (3) as well as detailed data patients receiving chemotherapy...
December 14, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29239468/the-importance-of-risk-factors-for-the-prediction-of-patients-with-invasive-pulmonary-aspergillosis
#13
Selçuk Kaya, Eda Gençalioğlu, Mehmet Sönmez, Iftihar Köksal
OBJECTIVE: Invasive pulmonary aspergillosis (IPA) is a major challenge in the management of immunocompromised patients. Despite all the advances in diagnosis, it remains a problem. The purpose of our study was to investigate the risk factors associated with IPA seen in patients with hematological malignancies. METHOD: A total of 152 febrile neutropenia (FEN) patients with hematological malignancies aged over 18 years and receiving high-dose chemotherapy or stem cell transplant between January 1, 2010, and December 31, 2012 were included in the study...
September 2017: Revista da Associação Médica Brasileira
https://www.readbyqxmd.com/read/29237905/a-clinical-study-of-polyethylene-glycol-recombinant-human-granulocyte-colony-stimulating-factor-prevention-neutropenia-syndrome-in-patients-with-esophageal-carcinoma-and-lung-cancer-after-concurrent-chemoradiotherapy
#14
Fang Liu, Yu Du, Boning Cai, Maohui Yan, Wei Yang, Qianqian Wang
OBJECTIVE: To compare the efficacy and safety of PEG-rhG-CSF and recombinant human G-CSF (rhG-CSF) for the prevention and delayed application in febrile neutropenia, hospitalization rate in concurrent chemoradiotherapy of tumors. METHODS: A total of 163 patients, who received concurrent chemoradiotherapy for solid tumors. There were 75 patients in the PEG-rhG-CSF group (PEG group), who received 146 cycles of concurrent chemoradiotherapy, of which 132 cycles (90...
2017: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/29233611/analysis-of-factors-associated-with-in-hospital-mortality-in-lung-cancer-chemotherapy-patients-with-neutropenia
#15
REVIEW
Julia Cupp, Eva Culakova, Marek S Poniewierski, David C Dale, Gary H Lyman, Jeffrey Crawford
Lung cancer, compared with other solid tumors, is associated with high mortality rates from febrile neutropenia. The risk factors associated with in-hospital mortality were identified and compared for patients with lung cancer and patients with other solid tumors. Hospitalization data from the University Health Consortium database inclusive of 2004 to 2012 were analyzed. The study population included all adult patients with solid tumors who developed neutropenia. Cancer type, the presence of neutropenia, and further subgroups were determined using International Classification of Diseases, 9th revision, Clinical Modification codes...
October 28, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29230663/advantages-with-prophylactic-peg-rhg-csf-versus-rhg-csf-in-breast-cancer-patients-receiving-multiple-cycles-of-myelosuppressive-chemotherapy-an-open-label-randomized-multicenter-phase-iii-study
#16
Jie Xie, Jun Cao, Jing-Fen Wang, Bai-Hong Zhang, Xiao-Hua Zeng, Hong Zheng, Yang Zhang, Li Cai, Yu-Dong Wu, Qiang Yao, Xiao-Chun Zhao, Wei-Dong Mao, Ai-Mei Jiang, Shao-Shui Chen, Shun-E Yang, Shu-Sen Wang, Jian-Hong Wang, Yue-Yin Pan, Bi-Yong Ren, Yan-Ju Chen, Li-Zhi Ouyang, Kai-Jian Lei, Jing-Hua Gao, Wen-He Huang, Zhan Huang, Tao Shou, Yan-Ling He, Jing Cheng, Yang Sun, Wei-Ming Li, Shu-de Cui, Xin Wang, Zhi-Guo Rao, Hu Ma, Wei Liu, Xue-Yong Wu, Wei-Xi Shen, Fei-Lin Cao, Ze-Min Xiao, Biao Wu, Shu-Yan Tian, Dong Meng, Peng Shen, Bi-Yun Wang, Zhonghua Wang, Jian Zhang, Leiping Wang, Xi-Chun Hu
BACKGROUND: PEG-rhG-CSF reduces neutropenia and improves chemotherapy safety. In China's registration trial (CFDA: 2006L01305), we assessed its efficacy and safety against rhG-CSF, and prospectively explored its value over multiple cycles of chemotherapy. METHODS: In this open-label, randomized, multicenter phase 3 study, breast cancer patients (n = 569) were randomized to receive PEG-rhG-CSF 100 µg/kg, PEG-rhG-CSF 6 mg, or rhG-CSF 5 µg/kg/d after chemotherapy...
December 11, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29230661/weak-circadian-rhythm-increases-neutropenia-risk-among-breast-cancer-patients-undergoing-adjuvant-chemotherapy
#17
Wentao Li, Carol Chi-Hei Kwok, Dominic Chun-Wan Chan, Feng Wang, Lap Ah Tse
PURPOSE: Severe neutropenia is a common dose-limiting side effect of adjuvant breast cancer chemotherapy. We aimed to test the hypothesis that weak circadian rhythm is associated with an increased risk of neutropenia using a cohort study. METHODS: We consecutively recruited 193 breast cancer patients who received adjuvant chemotherapy (5-fluorouracil, epirubicin, and cyclophosphamide followed by docetaxel; doxorubicin and cyclophosphamide; docetaxel and cyclophosphamide)...
December 11, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29227817/comparing-granulocyte-colony-stimulating-factor-filgrastim-and-pegfilgrastim-to-its-biosimilars-in-terms-of-efficacy-and-safety-a-meta-analysis-of-randomised-clinical-trials-in-breast-cancer-patients
#18
Edoardo Botteri, Andriy Krendyukov, Giuseppe Curigliano
BACKGROUND: Granulocyte colony-stimulating factors (G-CSFs) are widely used to prevent neutropenia in cancer patients undergoing myelosuppressive chemotherapy. Several biosimilar medicines of G-CSF are now available, with their development involving a step-wise series of comparisons to demonstrate similarity to reference biologics. Randomised clinical trials (RCTs) are considered confirmatory, and for G-CSF biosimilars, patients with breast cancer (BC) undergoing myelosuppressive chemotherapy are the most sensitive population in which to confirm similarity...
December 8, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29223991/a-patient-risk-model-of-chemotherapy-induced-febrile-neutropenia-lessons-learned-from-the-anc-study-group
#19
REVIEW
Gary H Lyman, Marek S Poniewierski
Neutropenia and its complications, including febrile neutropenia (FN), represent major toxicities associated with cancer chemotherapy, resulting in considerable morbidity, mortality, and costs. The myeloid growth factors such as granulocyte colony-stimulating factor (G-CSF) have been shown to reduce the risk of neutropenia complications while enabling safe and effective chemotherapy dose intensity. Concerns about the high costs of these agents along with limited physician adherence to clinical practice guidelines, resulting in both overuse and underuse, has stimulated interest in models for individual patient risk assessment to guide appropriate use of G-CSF...
December 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29222650/taxane-platinum-and-5-fu-prior-to-chemoradiotherapy-benefits-patients-with-stage-iv-neck-node-positive-head-and-neck-cancer-and-a-good-performance-status
#20
Natalie M Lowe, Jonathan M Bernstein, Kathleen Mais, Kate Garcez, Lip W Lee, Andrew Sykes, David J Thomson, Jarrod J Homer, Catharine M West, Nicholas J Slevin
PURPOSE: The benefit of adding docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy to chemoradiotherapy (CRT) in head and neck squamous cell carcinoma (HNSCC) remains uncertain. We aimed to investigate whether ICT is well tolerated when given with prophylactic treatment against predicted adverse effects and which patients benefit most. METHODS: A single-centre audit identified 132 HNSCC patients with stage IVa/b neck node-positive disease, prescribed TPF followed by CRT...
December 8, 2017: Journal of Cancer Research and Clinical Oncology
keyword
keyword
95633
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"